Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

e fatal to a child. Patients and their caregivers must be instructed to keep all tablets out of the reach of children. (See Information for Patients and Caregivers for disposal instructions.)

Due to the higher bioavailability of fentanyl in FENTORA, when converting patients from other oral fentanyl products, including oral transmucosal fentanyl citrate (OTFC and Actiq(R)), to FENTORA, do not substitute FENTORA on a mcg per mcg basis. Adjust doses as appropriate. (See DOSAGE AND ADMINISTRATION.)

FENTORA is intended to be used only in the care of opioid tolerant cancer patients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

Full prescribing information about FENTORA, including boxed warning, is available from http://www.FENTORA.com.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company, recently inducted into the World Economic Forum Community of Global Growth Companies. For 20 years, the company has been dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. Cephalon has delivered a seven-year compound annual growth rate (CAGR) through 2006 greater than 75% and 2006 revenue of $1.760 billion. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are loca
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, ... MarCom Awards for outstanding creative achievement by its marketing ... Award, the organization’s top honor, in the Branding category ... in April of this year. The event showcased top ... Nerium was awarded a Gold MarCom Award in the ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
(Date:11/26/2014)... MINNEAPOLIS , Nov. 25, 2014 Bio-Techne ... it has appointed Robert Gavin to serve ... of the Protein Platforms Division.  Mr. Gavin will be ... business segment, which includes the ProteinSimple business acquired in ... San Jose, California -based ProteinSimple ...
(Date:11/24/2014)... DUBAI , UAE, November 24, 2014 ... prestigious "Sheikh Hamdan Bin Rashid Al Maktoum Awards for ... in Dubai, United Arab Emirates , ... http://photos.prnewswire.com/prnh/20141124/717861 ) , The Carter Center ... Medical Services is actively involved in numerous programs that ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... Mass., Dec. 21 LeMaitre Vascular,Inc. (Nasdaq: ... and,implants, yesterday acquired Biomateriali S.r.l., a privately held ... cash, the assumption,of euro 0.8 million in intercompany ... 1.5 million. The acquisition was structured as a ...
... Dec. 20 MacAndrews & Forbes Holdings Inc.,announced ... President for Life,Sciences, who also serves as Chief ... to the National Biodefense Science Board (NBSB). The,NBSB ... Secretary Mike Leavitt,on scientific, technical and other matters ...
... the Record and Provide Accurate Information to ... ... VaxGen,Inc. (Pink Sheets: VXGN), (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ), ... announced on,November 12, 2007 that their respective Boards of Directors had ...
Cached Biology Technology:LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 2LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 3Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board 2VaxGen Addresses MPM Claims in Letter to Stockholders 2VaxGen Addresses MPM Claims in Letter to Stockholders 3VaxGen Addresses MPM Claims in Letter to Stockholders 4VaxGen Addresses MPM Claims in Letter to Stockholders 5VaxGen Addresses MPM Claims in Letter to Stockholders 6VaxGen Addresses MPM Claims in Letter to Stockholders 7VaxGen Addresses MPM Claims in Letter to Stockholders 8VaxGen Addresses MPM Claims in Letter to Stockholders 9
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... the world from dying off, deep cuts in carbon ... Carnegie,s Katharine Ricke and Ken Caldeira. They find that ... ocean chemistry conditions by the end of the century ... work will be published July 3 by Environmental ...
... A single systemic dose of special immune cells prevented ... model of kidney transplantation, according to experts at the ... available in the online version of the American ... eventual human trials of the technique. , Organ transplantation ...
... 4000 elk of the Clarks Fork herd leave crowded ... into the highlands of the Absaroka Mountains, where they ... snowmelt. It,s a short trip (40-60 kilometers) by migratory ... fences, metropolitan areas, and other human-built barriers. But it ...
Cached Biology News:Major changes needed for coral reef survival 2Dendritic cell therapy improves kidney transplant survival, Pitt team says 2Declining fortunes of Yellowstone's migratory elk 2Declining fortunes of Yellowstone's migratory elk 3Declining fortunes of Yellowstone's migratory elk 4
... Stainless Steel Staining tray 19 x 29 ... staining and blot processing.Automated staining of Coomassie ... nucleic acid analysis. Prepares blots for high ... control of protocol, solution, volume, and processing ...
Complement C1r [Human]...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... designs oligos for SYBR Green, TaqMan, LNA ... FRET assays. Highly specific primers are designed ... interpreting BLAST search results. Primer efficiency is ... by connecting to the Mfold server. Beacon ...
Biology Products: